...
首页> 外文期刊>Bioorganic and medicinal chemistry >Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors
【24h】

Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors

机译:设计,合成和评估2-氨基噻唑衍生物作为鞘氨醇激酶抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Sphingosine kinases (SphK1, SphK2) are main regulators of sphingosine-1-phosphate (S1P), which is a pleiotropic lipid mediator involved in numerous physiological and pathophysiological functions. SphKs are targets for novel anti-cancer and anti-inflammatory agents that can promote cell apoptosis and modulate autoimmune diseases. Herein, we describe the design, synthesis and evaluation of an aminothiazole class of SphK inhibitors. Potent inhibitors have been discovered through a series of modifications using the known SKI-II scaffold to define structure-activity relationships. We identified N-(4-methylthiazol-2- yl)-(2,4'-bithiazol)-2'-amine (24, ST-1803; IC50 values: 7.3 mu M (SphK1), 6.5 mu M (SphK2)) as a promising candidate for further in vivo investigations and structural development. (C) 2014 Elsevier Ltd. All rights reserved.
机译:鞘氨醇激酶(SphK1,SphK2)是鞘氨醇-1-磷酸酯(S1P)的主要调节剂,磷酸肌醇-1-磷酸酯是一种多效脂质介体,参与多种生理和病理生理功能。 SphK是新型抗癌和抗炎剂的靶标,这些抗癌剂和抗炎剂可促进细胞凋亡并调节自身免疫性疾病。在本文中,我们描述了氨基噻唑类SphK抑制剂的设计,合成和评估。通过使用已知的SKI-II支架定义结构-活性关系的一系列修饰,发现了有效的抑制剂。我们鉴定出N-(4-甲基噻唑-2-基)-(2,4'-噻唑)-2'-胺(24,ST-1803; IC50值:7.3μM(SphK1),6.5μM(SphK2) )作为进一步的体内研究和结构开发的有希望的候选者。 (C)2014 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号